MCID: PYR039
MIFTS: 47

Peyronie Disease

Categories: Rare diseases, Reproductive diseases

Aliases & Classifications for Peyronie Disease

MalaCards integrated aliases for Peyronie Disease:

Name: Peyronie Disease 58 77 54 56 74
Penile Curvature 54

Characteristics:

OMIM:

58
Inheritance:
male-limited, autosomal dominant


Classifications:



External Ids:

OMIM 58 171000
MedGen 43 C0030848
UMLS 74 C0030848

Summaries for Peyronie Disease

NIH Rare Diseases : 54 Peyronie disease is a connective tissue disorder characterized by a plaque, or hard lump, that forms within the penis. Affected individuals may experience painful, curved erections which can make make normal sexual intercourse impossible. Symptoms may appear suddenly or develop gradually. While the painful erections for most men resolve over time, the scar tissue and curvature may remain. Some cases appear to resolve spontaneously. The exact cause of Peyronie's disease is not known.

MalaCards based summary : Peyronie Disease, also known as penile curvature, is related to peyronie's disease and impotence. An important gene associated with Peyronie Disease is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Pathways in cancer. The drugs Ropivacaine and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and small intestine, and related phenotypes are abnormality of the genitourinary system and dupuytren contracture

Wikipedia : 77 Peyronie''s disease is a connective tissue disorder involving the growth of fibrous plaques in the soft... more...

Description from OMIM: 171000

Related Diseases for Peyronie Disease

Graphical network of the top 20 diseases related to Peyronie Disease:



Diseases related to Peyronie Disease

Symptoms & Phenotypes for Peyronie Disease

Human phenotypes related to Peyronie Disease:

33
# Description HPO Frequency HPO Source Accession
1 abnormality of the genitourinary system 33 HP:0000119
2 dupuytren contracture 33 HP:0005679

Symptoms via clinical synopsis from OMIM:

58
G U:
penile contracture

Limbs:
associated dupuytren contracture

Clinical features from OMIM:

171000

MGI Mouse Phenotypes related to Peyronie Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.46 NOS2 SMAD4 SOD1 TGFB1
2 muscle MP:0005369 9.26 NOS2 SMAD4 SOD1 TGFB1
3 neoplasm MP:0002006 8.92 NOS2 SMAD4 SOD1 TGFB1

Drugs & Therapeutics for Peyronie Disease

Drugs for Peyronie Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
2
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
3
Testosterone undecanoate Approved, Investigational Phase 4,Phase 1 5949-44-0
4
Testosterone Approved, Experimental, Investigational Phase 4,Phase 1 58-22-0, 481-30-1 6013 10204
5
Methyltestosterone Approved Phase 4,Phase 1 58-18-4 6010
6
Testosterone enanthate Approved Phase 4,Phase 1 315-37-7 9416
7 Neurotransmitter Agents Phase 4,Phase 2
8 Peripheral Nervous System Agents Phase 4,Phase 2,Not Applicable
9 Adrenergic alpha-2 Receptor Agonists Phase 4
10 Anesthetics Phase 4,Phase 2,Not Applicable
11 Central Nervous System Depressants Phase 4,Phase 2,Not Applicable
12 Adrenergic Agents Phase 4
13 Adrenergic Agonists Phase 4
14 Analgesics Phase 4,Phase 2,Not Applicable
15 Analgesics, Non-Narcotic Phase 4,Not Applicable
16 Hypnotics and Sedatives Phase 4
17 Adrenergic alpha-Agonists Phase 4
18 Anesthetics, Local Phase 4,Phase 2,Not Applicable
19 Testosterone 17 beta-cypionate Phase 4,Phase 1
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 1
21 Antineoplastic Agents, Hormonal Phase 4,Phase 1
22 Hormone Antagonists Phase 4,Phase 1
23 Hormones Phase 4,Phase 1
24 Androgens Phase 4,Phase 1
25 Anabolic Agents Phase 4,Phase 1
26
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
27
Lidocaine Approved, Vet_approved Phase 2,Not Applicable 137-58-6 3676
28
Chlorhexidine Approved, Vet_approved Phase 2 55-56-1 2713 9552079
29 Neuromuscular Agents Phase 2
30 Botulinum Toxins, Type A Phase 2
31 Acetylcholine Release Inhibitors Phase 2
32 abobotulinumtoxinA Phase 2
33 Botulinum Toxins Phase 2
34 Cholinergic Agents Phase 2
35 Pharmaceutical Solutions Phase 2
36 Anti-Infective Agents Phase 2,Not Applicable
37 Anti-Arrhythmia Agents Phase 2,Not Applicable
38 Sodium Channel Blockers Phase 2,Not Applicable
39 Diuretics, Potassium Sparing Phase 2,Not Applicable
40 Dermatologic Agents Phase 2
41 Disinfectants Phase 2
42 Anti-Infective Agents, Local Phase 2
43 Chlorhexidine gluconate Phase 2
44
Tocopherol Approved, Investigational Phase 1 1406-66-2 14986
45
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1 59-02-9 14985
46
Calcium Approved, Nutraceutical Phase 1 7440-70-2 271
47
Ergocalciferol Approved, Nutraceutical Phase 1 50-14-6 5280793
48
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1 1406-16-2
49 Tocotrienol Investigational Phase 1 6829-55-6
50 Vitamin D2 Phase 1

Interventional clinical trials:

(show all 29)
# Name Status NCT ID Phase Drugs
1 Effects of Dexmedetomidine as Adjunct to Pudendal Block for Pediatric Penile Surgery Completed NCT02848157 Phase 4 Dexmedetomidine;plain ropivacaine;Ropivacaine
2 Treatment Response to Xiaflex for Men With Peyronie's Disease Recruiting NCT03774264 Phase 4 Xiaflex
3 Xiaflex® Plus Testosterone Treatment Pilot Study Protocol Recruiting NCT03815331 Phase 4 Xiaflex®;Aveed
4 Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response Recruiting NCT03767452 Phase 4 Xiaflex® 0.58 mg
5 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01685437 Phase 3
6 A Study of AA4500 in Men With Peyronie's Disease Completed NCT01243411 Phase 3
7 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221597 Phase 3
8 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221623 Phase 3
9 An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease Completed NCT02267460 Phase 3
10 H-22411: BOTOX® for Peyronie's Disease Unknown status NCT00812838 Phase 2 100 units of Botulinum Toxin Type A
11 Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) Unknown status NCT01184586 Phase 2
12 The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Completed NCT00755222 Phase 2
13 Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease Completed NCT01430169 Phase 2
14 Intracavernosal Injection of Botulinum Toxin Type A (50 and 100 Unit) in the Treatment of Erectile Dysfunction Completed NCT03355963 Phase 2
15 Urethral Sterilization With Chlorhexidine Digluconate to Facilitate Primary Repair & Same-Session Implantation Recruiting NCT03614429 Phase 2 Chlorhexidine gel will be prepared according to an international product Instillagel®
16 Clostridium Histolyticum Collagenase Injection for Urethral Disease Not yet recruiting NCT02948842 Phase 2 Clostridium Histolyticum Collagenase;Lidocaine
17 Peyronie's Disease Treatment Protocol Completed NCT02072018 Phase 1 H-100;Placebo
18 Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease Completed NCT01578473 Phase 1 Vitamin D2;Vitamin E;Testosterone Pellets
19 Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD Completed NCT02395029 Phase 1
20 Management of Peyronie's Disease With Adipose Tissue Stem Cell Unknown status NCT02414308 Not Applicable Adipose tissue stem cell injection
21 Efficacy of Extracorporal Shock Wave Therapy in Patient With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830 Not Applicable
22 Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease Completed NCT02298829 Subjects Previously Treated with AA4500
23 Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy Completed NCT00800813
24 Penile Fracture: A Comparison of Erectile Function After Immediate Repair Versus Delayed Repair Completed NCT03449940 Not Applicable Lidocaine;Ceftriaxone;Diclofenac Sodium
25 Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease. Recruiting NCT03530540 Not Applicable
26 Penile Length Maintenance Post-Prostatectomy Recruiting NCT03500419 Not Applicable
27 Penile Length Restoration in Men With Diabetes Mellitus, Type II Recruiting NCT03756688 Not Applicable
28 Efficacy of Penile Traction Therapy Using a Novel Device Active, not recruiting NCT03389854 Not Applicable
29 Outcomes of Surgical Correction of Penile Curvature in Adult Not yet recruiting NCT03313986

Search NIH Clinical Center for Peyronie Disease

Genetic Tests for Peyronie Disease

Anatomical Context for Peyronie Disease

MalaCards organs/tissues related to Peyronie Disease:

42
Bone, Prostate, Small Intestine

Publications for Peyronie Disease

Articles related to Peyronie Disease:

(show top 50) (show all 201)
# Title Authors Year
1
Re: Clinical Experience with Penile Traction Therapy among Men Undergoing Collagenase Clostridium Histolyticum for Peyronie Disease. ( 29310171 )
2018
2
Separating the Wheat From the Chaff: An Evaluation of Readability, Quality, and Accuracy of Online Health Information for Treatment of Peyronie Disease. ( 29723588 )
2018
3
Penile Reconstructive Surgery in Peyronie Disease: Challenges in Restoring Normal Penis Size, Shape, and Function. ( 29623703 )
2018
4
A Novel Noninvasive Ultrasound Vibro-elastography Technique for Assessing Patients With Erectile Dysfunction and Peyronie Disease. ( 29548864 )
2018
5
Primary Treatment of Peyronie's Disease: A 55-yr-old Male with 45° Dorsal Penile Curvature and Good Erectile Function. ( 30369422 )
2018
6
Long-term Results of Ventral Penile Curvature Repair in Childhood. ( 29051007 )
2018
7
Reconstructive surgery for recurrent penile curvature. ( 29058072 )
2018
8
Re: An unanswered question in pediatric urology: the post pubertal persistence of prepubertal congenital penile curvature correction by tunical plication. ( 29244267 )
2018
9
REPLY BY THE AUTHORS: Re: An unanswered question in pediatric urology: the post pubertal persistence of prepubertal congenital penile curvature correction by tunical plication. ( 29244268 )
2018
10
Objective measurements of the penile angulation are significantly different than self-estimated magnitude among patients with penile curvature. ( 29570261 )
2018
11
Modified 16-Dot plication technique for correction of penile curvature: prevention of knot-related complications. ( 29736012 )
2018
12
Re: Objective Measurements of the Penile Angulation are Significantly Different than Self-Estimated Magnitude among Patients with Penile Curvature. ( 30227550 )
2018
13
Prevalence of penile curvature: a population-based cross-sectional study in metropolitan and rural cities in Australia. ( 30387224 )
2018
14
Impact of Camera Deviation on Penile Curvature Assessment Using 2D Pictures. ( 30415815 )
2018
15
Clinical Experience With Penile Traction Therapy Among Men Undergoing Collagenase Clostridium histolyticum for Peyronie Disease. ( 28347795 )
2017
16
Small Intestinal Submucosa Grafting for Peyronie Disease: Outcomes and Patient Satisfaction. ( 27825744 )
2017
17
Factors Associated With Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients With Peyronie Disease. ( 28554517 )
2017
18
Safety Profile of Collagenase Clostridium Histolyticum Stratified by Degree of Penile Curvature in Patients With Peyronie Disease. ( 28502596 )
2017
19
Re: Factors Associated with Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients with Peyronie Disease. ( 29144914 )
2017
20
Self-reported Clinical Meaningfulness Early in the Treatment Course Predicts Objective Outcomes in Men Undergoing Collagenase Clostridium histolyticum Injections for Peyronie Disease. ( 28483591 )
2017
21
Re: Clinical Experience with Penile Traction Therapy among Men Undergoing Collagenase Clostridium histolyticum for Peyronie Disease. ( 28817884 )
2017
22
Re: Small Intestinal Submucosa Grafting for Peyronie Disease: Outcomes and Patient Satisfaction. ( 29059762 )
2017
23
Congenital prepubic sinus (an epispadiac variant of dorsal urethral duplication) with dorsal penile curvature in an adult man: a rare association. ( 28596205 )
2017
24
Patient-reported long-term sexual outcomes following plication surgery for penile curvature: A retrospective 58-patient study. ( 27867021 )
2017
25
Re: Do Adult Men with Untreated Ventral Penile Curvature Have Adverse Outcomes? ( 27979563 )
2017
26
Patient satisfaction with correction of congenital penile curvature. ( 29292041 )
2017
27
Partial Plaque Excision and Grafting With Collagen Fleece in Peyronie Disease. ( 26953837 )
2016
28
The Genetic Basis of Peyronie Disease: A Review. ( 27872008 )
2016
29
Shaeer's Corporal Rotation III: Shortening-Free Correction of Congenital Penile Curvature-The Noncorporotomy Technique. ( 26298209 )
2016
30
Do adult men with untreated ventral penile curvature have adverse outcomes? ( 26776946 )
2016
31
The Efficacy of Congenital Penile Curvature Repair in Preadolescent Males: Early Outcomes. ( 26845052 )
2016
32
Penile curvature: an update for management from 20 years experience in a high volume centre. ( 27103093 )
2016
33
Re: Evaluation of the Treatment of Congenital Penile Curvature including Psychosexual Assessment. ( 27186747 )
2016
34
Geometrical modified nesbit corporoplasty to correct different types of penile curvature: description of the surgical procedure based on geometrical principles and long-term results. ( 27511302 )
2016
35
Re: The Efficacy of Congenital Penile Curvature Repair in Preadolescent Males: Early Outcomes. ( 27845136 )
2016
36
Effects of Stem Cell Treatment in Human Patients With Peyronie Disease. ( 26414724 )
2015
37
Re: Corporoplasty Using Buccal Mucosa Graft in Peyronie Disease: Is it a First Choice? ( 26088238 )
2015
38
Corporoplasty using buccal mucosa graft in Peyronie disease: is it a first choice? ( 25582815 )
2015
39
Intralesional Injections for Early Peyronie Disease: Standardized Assessment and Analysis of Predictive Factors for Treatment Response. ( 26142583 )
2015
40
Intralesional Injection of Interferon-α2b Improves Penile Curvature in Men with Peyronie's Disease Independent of Plaque Location. ( 26144333 )
2015
41
The Egydio geometrical procedure for managing penile curvature using a single relaxing incision: A single-centre experience with 330 patients. ( 26609449 )
2015
42
Re: The STAGE technique (superficial tunica albuginea geometric-based excision) for the correction of biplanar congenital penile curvature. ( 25617297 )
2015
43
Rotation of the corpora cavernosa for the treatment of congenital penile curvature. ( 25667175 )
2015
44
A new corporoplasty based on stratified structure of tunica albuginea for the treatment of congenital penile curvature - long-term results. ( 25914848 )
2015
45
Multiple urethral anomalies: Parameatal urethral cyst, penile curvature, incomplete hypospadiac anterior duplication of the urethra and distal hipospadias. ( 26029298 )
2015
46
Evaluation of the Treatment of Congenital Penile Curvature Including Psychosexual Assessment. ( 26139203 )
2015
47
Editorial Comment on "Evaluation of the Treatment of Congenital Penile Curvature including Psycho-Sexual Assessment". ( 26255808 )
2015
48
Lingual mucosal graft in treatment of Peyronie disease. ( 25283703 )
2014
49
The anti-inflammatory and antifibrosis effects of anthocyanin extracted from black soybean on a Peyronie disease rat model. ( 25156514 )
2014
50
Re: clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. ( 24289857 )
2014

Variations for Peyronie Disease

Expression for Peyronie Disease

Search GEO for disease gene expression data for Peyronie Disease.

Pathways for Peyronie Disease

Pathways related to Peyronie Disease according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.43 IFNA2 NOS2 PDE5A SOD1 TGFB1
2 12.18 IFNA2 NOS2 SMAD4 TGFB1
3 11.8 IFNA2 NOS2 TGFB1
4 11.72 NOS2 SMAD4 TGFB1
5 11.63 SMAD4 TGFB1
6 11.61 NOS2 TGFB1
7 11.6 SMAD4 TGFB1
8
Show member pathways
11.59 SMAD4 TGFB1
9 11.57 SMAD4 TGFB1
10 11.52 NOS2 SOD1
11 11.47 IFNA2 TGFB1
12 11.45 SMAD4 TGFB1
13 11.44 NOS2 TGFB1
14
Show member pathways
11.42 SMAD4 TGFB1
15 11.39 NOS2 SOD1
16 11.37 NOS2 SMAD4
17
Show member pathways
11.32 NOS2 SOD1
18 11.3 SMAD4 TGFB1
19 11.23 SMAD4 TGFB1
20
Show member pathways
11.13 NOS2 PDE5A
21
Show member pathways
11.1 NOS2 SOD1
22 11.05 IFNA2 NOS2
23 10.93 SMAD4 TGFB1
24
Show member pathways
10.86 SMAD4 TGFB1
25 10.66 SMAD4 TGFB1
26 10.51 NOS2 SMAD4 TGFB1
27 10.37 NOS2 PDE5A

GO Terms for Peyronie Disease

Cellular components related to Peyronie Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 8.62 SOD1 TGFB1

Biological processes related to Peyronie Disease according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.77 IFNA2 SMAD4 TGFB1
2 cytokine-mediated signaling pathway GO:0019221 9.67 IFNA2 NOS2 TGFB1
3 negative regulation of gene expression GO:0010629 9.63 IFNA2 NOS2 TGFB1
4 transforming growth factor beta receptor signaling pathway GO:0007179 9.6 SMAD4 TGFB1
5 response to organic substance GO:0010033 9.58 SOD1 TGFB1
6 positive regulation of MAP kinase activity GO:0043406 9.58 PDE5A TGFB1
7 cellular iron ion homeostasis GO:0006879 9.57 SMAD4 SOD1
8 SMAD protein signal transduction GO:0060395 9.56 SMAD4 TGFB1
9 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.55 SMAD4 TGFB1
10 positive regulation of epithelial to mesenchymal transition GO:0010718 9.54 SMAD4 TGFB1
11 regulation of cell proliferation GO:0042127 9.54 NOS2 SMAD4 TGFB1
12 negative regulation of T cell proliferation GO:0042130 9.52 PDE5A TGFB1
13 ovarian follicle development GO:0001541 9.51 SMAD4 SOD1
14 response to hypoxia GO:0001666 9.5 NOS2 SMAD4 TGFB1
15 endoderm development GO:0007492 9.48 SMAD4 TGFB1
16 superoxide metabolic process GO:0006801 9.43 NOS2 SOD1
17 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.4 SMAD4 TGFB1
18 positive regulation of superoxide anion generation GO:0032930 9.26 SOD1 TGFB1
19 positive regulation of SMAD protein signal transduction GO:0060391 9.16 SMAD4 TGFB1
20 SMAD protein complex assembly GO:0007183 8.96 SMAD4 TGFB1
21 regulation of binding GO:0051098 8.62 SMAD4 TGFB1

Molecular functions related to Peyronie Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 8.92 NOS2 SMAD4 SOD1 TGFB1

Sources for Peyronie Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....